OTC Switch Interest Cooled By Study Costs To Update Safety Data

Firms often are hesitant to prepare Rx-to-OTC switch applications because safety and efficacy data for their products are over a decade old, notes health care consultant Laura Mahecha.

Binocular viewer_1200X675

Pharmaceutical firms get cold feet about potential OTC switches when they consider the costs for studies to update safety data for an ingredient, suggests Laura Mahecha, a health care market consultant for research firm Kline & Co.

During a June 27 webinar, “Key Issues Trending in the US OTC Market,” Mahecha noted that with safety "paramount for...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Rx-to-OTC Switch

More from Health